Dr. Aseem Malhotra & Gary Brecka discuss statin research & cholesterol in this 3:18 clip: - Malhotra cites John Ioannidis (Stanford, most-cited medical researcher): Greater financial interests in a field → higher chance findings may not hold up - Statins: Most prescribed for primary prevention (no prior heart event) — industry trials show ~1 in 100 benefit (non-fatal event prevention) over 5 years, no life extension in best-case scenario - He emphasizes sharing this with patients for informed decisions - Both note: When adjusting for triglycerides/HDL (tied to insulin resistance), LDL alone is not an independent risk factor for heart disease - In older adults (>60), higher LDL correlates with greater longevity (potential immune role) Clip here — thoughtful conversation on statin evidence & cholesterol views 👇 What do you think about financial influence on medical research? Or how should patients weigh benefit stats like 1 in 100? Honest thoughts — no judgment.